The Food and Drug Administration (FDA) has approved six urinary biomarker tests for the diagnosis of bladder cancer: quantitative nuclear matrix protein 22 (NMP22; Alere NMP22 Test), qualitative NMP22 (NMP22BladderChek), qualitative bladder tumor antigen (BTA; BTA stat test), quantitative BTA (BTA TRAK), fluorescence in situ hybridization (UroVysion), and fluorescent immunohistochemistry (ImmunoCyt) [10]. Here, NUMA1 is linked to urinary bladder carcinoma.